Sarepta Therapeutics, Inc. (0L35.L)
USD 122.56
(-2.47%)
USD 122.56
(-2.47%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -535.97 Million USD | 23.81% |
| 2022 | -703.48 Million USD | -67.99% |
| 2021 | -418.78 Million USD | 24.43% |
| 2020 | -554.12 Million USD | 22.51% |
| 2019 | -715.07 Million USD | -97.58% |
| 2018 | -361.91 Million USD | -614.01% |
| 2017 | -50.68 Million USD | 81.03% |
| 2016 | -267.26 Million USD | -21.47% |
| 2015 | -220.03 Million USD | -62.04% |
| 2014 | -135.78 Million USD | -21.26% |
| 2013 | -111.98 Million USD | 7.67% |
| 2012 | -121.28 Million USD | -5132.4% |
| 2011 | -2.31 Million USD | 92.8% |
| 2010 | -32.17 Million USD | -27.89% |
| 2009 | -25.15 Million USD | -5.04% |
| 2008 | -23.95 Million USD | 11.83% |
| 2007 | -27.16 Million USD | 12.57% |
| 2006 | -31.07 Million USD | -86.34% |
| 2005 | -16.67 Million USD | 32.7% |
| 2004 | -24.77 Million USD | -69.52% |
| 2003 | -14.61 Million USD | 50.21% |
| 2002 | -29.35 Million USD | -9.04% |
| 2001 | -26.92 Million USD | -191.4% |
| 2000 | -9.23 Million USD | -11.32% |
| 1999 | -8.3 Million USD | 68.91% |
| 1998 | -26.7 Million USD | -641.67% |
| 1997 | -3.6 Million USD | -71.43% |
| 1996 | -2.1 Million USD | 19.23% |
| 1995 | -2.6 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 36.11 Million USD | -20.89% |
| 2024 Q2 | 6.46 Million USD | -82.11% |
| 2023 Q2 | -23.94 Million USD | 95.37% |
| 2023 Q4 | 45.65 Million USD | 211.53% |
| 2023 Q3 | -40.93 Million USD | -71.0% |
| 2023 FY | -535.97 Million USD | 23.81% |
| 2023 Q1 | -516.75 Million USD | -373.03% |
| 2022 Q3 | -257.73 Million USD | -11.34% |
| 2022 FY | -703.48 Million USD | -67.99% |
| 2022 Q4 | -109.24 Million USD | 57.61% |
| 2022 Q1 | -105.02 Million USD | 13.9% |
| 2022 Q2 | -231.48 Million USD | -120.41% |
| 2021 Q4 | -121.98 Million USD | -153.37% |
| 2021 Q1 | -167.25 Million USD | 11.66% |
| 2021 Q2 | -81.4 Million USD | 51.33% |
| 2021 FY | -418.78 Million USD | 24.43% |
| 2021 Q3 | -48.14 Million USD | 40.86% |
| 2020 Q3 | -196.49 Million USD | -30.29% |
| 2020 FY | -554.12 Million USD | 22.51% |
| 2020 Q1 | -17.49 Million USD | 92.58% |
| 2020 Q2 | -150.82 Million USD | -762.22% |
| 2020 Q4 | -189.31 Million USD | 3.65% |
| 2019 Q3 | -126.32 Million USD | 54.3% |
| 2019 Q1 | -76.64 Million USD | 45.6% |
| 2019 Q2 | -276.4 Million USD | -260.64% |
| 2019 Q4 | -235.7 Million USD | -86.58% |
| 2019 FY | -715.07 Million USD | -97.58% |
| 2018 Q1 | -35.36 Million USD | -47.36% |
| 2018 Q4 | -140.89 Million USD | -84.43% |
| 2018 Q3 | -76.39 Million USD | 30.09% |
| 2018 FY | -361.91 Million USD | -614.01% |
| 2018 Q2 | -109.26 Million USD | -208.99% |
| 2017 Q4 | -23.99 Million USD | 49.73% |
| 2017 FY | -50.68 Million USD | 81.03% |
| 2017 Q3 | -47.73 Million USD | 24.29% |
| 2017 Q2 | -63.04 Million USD | -174.97% |
| 2017 Q1 | 84.09 Million USD | 195.07% |
| 2016 Q4 | -88.45 Million USD | -55.88% |
| 2016 Q2 | -62.3 Million USD | -4.23% |
| 2016 FY | -267.26 Million USD | -21.47% |
| 2016 Q1 | -59.77 Million USD | 7.59% |
| 2016 Q3 | -56.74 Million USD | 8.92% |
| 2015 FY | -220.03 Million USD | -62.04% |
| 2015 Q4 | -64.68 Million USD | -24.53% |
| 2015 Q3 | -51.93 Million USD | -24.1% |
| 2015 Q2 | -41.85 Million USD | 32.01% |
| 2015 Q1 | -61.55 Million USD | -38.6% |
| 2014 FY | -135.78 Million USD | -21.26% |
| 2014 Q2 | -33.87 Million USD | -19.81% |
| 2014 Q3 | -29.22 Million USD | 13.72% |
| 2014 Q4 | -44.41 Million USD | -51.97% |
| 2014 Q1 | -28.27 Million USD | -220.56% |
| 2013 Q2 | -19.05 Million USD | 54.73% |
| 2013 Q3 | -42.03 Million USD | -120.62% |
| 2013 Q4 | -8.82 Million USD | 79.01% |
| 2013 Q1 | -42.08 Million USD | 32.2% |
| 2013 FY | -111.98 Million USD | 7.67% |
| 2012 FY | -121.28 Million USD | -5132.4% |
| 2012 Q1 | -17.7 Million USD | -1155.6% |
| 2012 Q2 | 8.03 Million USD | 145.4% |
| 2012 Q3 | -49.55 Million USD | -716.5% |
| 2012 Q4 | -62.06 Million USD | -25.25% |
| 2011 Q3 | -4.02 Million USD | -414.31% |
| 2011 Q1 | 1.83 Million USD | 123.98% |
| 2011 Q4 | -1.41 Million USD | 64.93% |
| 2011 Q2 | 1.27 Million USD | -30.22% |
| 2011 FY | -2.31 Million USD | 92.8% |
| 2010 Q1 | -584 Thousand USD | -116.57% |
| 2010 FY | -32.17 Million USD | -27.89% |
| 2010 Q2 | -16.65 Million USD | -2752.05% |
| 2010 Q3 | -7.29 Million USD | 56.21% |
| 2010 Q4 | -7.64 Million USD | -4.81% |
| 2009 FY | -25.15 Million USD | -5.04% |
| 2009 Q3 | -8.09 Million USD | 58.87% |
| 2009 Q4 | 3.52 Million USD | 143.57% |
| 2009 Q2 | -19.66 Million USD | -2021.68% |
| 2009 Q1 | -927 Thousand USD | 18.72% |
| 2008 FY | -23.95 Million USD | 11.83% |
| 2008 Q3 | -6.04 Million USD | -245.42% |
| 2008 Q2 | -1.75 Million USD | 88.34% |
| 2008 Q1 | -15.01 Million USD | -263.79% |
| 2008 Q4 | -1.14 Million USD | 81.14% |
| 2007 Q2 | -8.53 Million USD | 12.2% |
| 2007 FY | -27.16 Million USD | 12.57% |
| 2007 Q4 | -4.12 Million USD | 41.33% |
| 2007 Q3 | -7.03 Million USD | 17.59% |
| 2007 Q1 | -9.72 Million USD | -16.73% |
| 2006 FY | -31.07 Million USD | -86.34% |
| 2006 Q4 | -8.32 Million USD | -22.84% |
| 2006 Q3 | -6.78 Million USD | 1.76% |
| 2006 Q2 | -6.9 Million USD | 23.83% |
| 2006 Q1 | -9.06 Million USD | -99.08% |
| 2005 Q2 | -4.93 Million USD | 10.3% |
| 2005 Q1 | -5.49 Million USD | -10.2% |
| 2005 Q4 | -4.55 Million USD | -168.93% |
| 2005 Q3 | -1.69 Million USD | 65.69% |
| 2005 FY | -16.67 Million USD | 32.7% |
| 2004 FY | -24.77 Million USD | -69.52% |
| 2004 Q3 | -5.1 Million USD | 28.55% |
| 2004 Q4 | -4.99 Million USD | 2.29% |
| 2004 Q2 | -7.14 Million USD | 5.11% |
| 2004 Q1 | -7.53 Million USD | -143.28% |
| 2003 Q1 | -3.41 Million USD | 14.4% |
| 2003 Q4 | -3.09 Million USD | 32.74% |
| 2003 FY | -14.61 Million USD | 50.21% |
| 2003 Q2 | -3.49 Million USD | -2.31% |
| 2003 Q3 | -4.6 Million USD | -31.61% |
| 2002 Q4 | -3.99 Million USD | 43.36% |
| 2002 Q1 | -7.81 Million USD | -69.76% |
| 2002 Q2 | -10.49 Million USD | -34.31% |
| 2002 Q3 | -7.05 Million USD | 32.83% |
| 2002 FY | -29.35 Million USD | -9.04% |
| 2001 Q4 | -4.6 Million USD | 70.48% |
| 2001 FY | -26.92 Million USD | -191.4% |
| 2001 Q3 | -15.59 Million USD | -339.82% |
| 2001 Q2 | -3.54 Million USD | -11.56% |
| 2001 Q1 | -3.17 Million USD | -5.69% |
| 2000 Q3 | -2.25 Million USD | 20.71% |
| 2000 Q2 | -2.84 Million USD | -149.18% |
| 2000 FY | -9.23 Million USD | -11.32% |
| 2000 Q1 | -1.13 Million USD | 52.5% |
| 2000 Q4 | -3 Million USD | -33.54% |
| 1999 Q1 | -1.7 Million USD | 29.17% |
| 1999 FY | -8.3 Million USD | 68.91% |
| 1999 Q3 | -2.2 Million USD | -10.0% |
| 1999 Q4 | -2.4 Million USD | -9.09% |
| 1999 Q2 | -2 Million USD | -17.65% |
| 1998 Q2 | -1.7 Million USD | -21.43% |
| 1998 FY | -26.7 Million USD | -641.67% |
| 1998 Q4 | -2.4 Million USD | 88.73% |
| 1998 Q3 | -21.3 Million USD | -1152.94% |
| 1998 Q1 | -1.4 Million USD | -75.0% |
| 1997 Q1 | -300 Thousand USD | 55.22% |
| 1997 Q2 | -1.3 Million USD | -333.33% |
| 1997 Q3 | -900 Thousand USD | 30.77% |
| 1997 FY | -3.6 Million USD | -71.43% |
| 1997 Q4 | -800 Thousand USD | 11.11% |
| 1996 Q3 | -580 Thousand USD | 0.0% |
| 1996 Q1 | -250 Thousand USD | 0.0% |
| 1996 Q2 | -580 Thousand USD | -132.0% |
| 1996 Q4 | -670 Thousand USD | -15.52% |
| 1996 FY | -2.1 Million USD | 19.23% |
| 1995 FY | -2.6 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | -249.811% |
| Dynavax Technologies Corporation | -6.38 Million USD | -8289.059% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 40827.736% |
| Perrigo Company plc | -12.7 Million USD | -4120.291% |
| Illumina, Inc. | -1.16 Billion USD | 53.835% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 108.94% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | -20.705% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 93.794% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 139.468% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -384.788% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 113.557% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -1244.649% |
| Waters Corporation | 642.23 Million USD | 183.455% |
| Biogen Inc. | 1.16 Billion USD | 146.161% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -107.879% |
| Evolus, Inc. | -61.68 Million USD | -768.894% |
| Adicet Bio, Inc. | -142.65 Million USD | -275.708% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -352.252% |
| bluebird bio, Inc. | -211.91 Million USD | -152.923% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -156.144% |
| FibroGen, Inc. | -284.23 Million USD | -88.57% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 143.224% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -1101.653% |
| Homology Medicines, Inc. | -53.74 Million USD | -897.296% |
| Geron Corporation | -184.12 Million USD | -191.091% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | -21.746% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -253.584% |
| Myriad Genetics, Inc. | -112 Million USD | -378.551% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -523.991% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | -11.385% |
| Zoetis Inc. | 2.34 Billion USD | 122.866% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -889.106% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 167.95% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 419.71% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 114.808% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -1170.118% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | -46.327% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | -94.106% |
| Verastem, Inc. | -87.36 Million USD | -513.478% |
| Nektar Therapeutics | -276.05 Million USD | -94.155% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -124.035% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -505.754% |
| OPKO Health, Inc. | -188.86 Million USD | -183.791% |
| Exelixis, Inc. | 207.76 Million USD | 357.973% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 314.648% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 604.972% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -1028.254% |
| uniQure N.V. | -308.47 Million USD | -73.749% |
| Imunon, Inc. | -19.51 Million USD | -2646.491% |
| Blueprint Medicines Corporation | -506.98 Million USD | -5.719% |
| Insmed Incorporated | -749.56 Million USD | 28.495% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 290.337% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | -52.228% |
| TG Therapeutics, Inc. | 12.67 Million USD | 4329.616% |
| Incyte Corporation | 597.59 Million USD | 189.688% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 29.523% |